Yulong Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yulong Liu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Hong Gong
Department of Military Cognitive Psychology, School of Psychology, Third Military Medical University (Army Medical University), Chongqing, China
2 shared publications Jiayin Liu
Department of Military Cognitive Psychology, School of Psychology Third Military Medical University (Army Medical University) Chongqing China
2 shared publicationsJing Luo
Department of Military Cognitive Psychology, School of Psychology Third Military Medical University (Army Medical University) Chongqing China
2 shared publicationsJinghui Zhao
Department of Military Cognitive Psychology, School of Psychology Third Military Medical University (Army Medical University) Chongqing China
2 shared publicationsLian Wang
Department of Military Cognitive Psychology, School of Psychology Third Military Medical University (Army Medical University) Chongqing China
2 shared publications- Xiaotang Fan
Department of Military Cognitive Psychology, School of Psychology, Army Medical University, Chongqing, China
2 shared publications
Latest Publications
- Open Access
- 28 November 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (12) , e70654
Naringin Alleviates Autistic‐Like Behaviors in BTBR Mice Through Cannabinoid Receptor Type 1‐Mediated Restoration of Hippocampal Neurogenesis
Background: Naringin, a flavanone glycoside (naringenin 7‐O‐neohesperidose), exhibits a broad range of pharmacological activities, including neuroprotection. However, its effects on autistic‐like behavior have not been extensively studied. Methods: In this investigation, we utilized the autistic BTBR T + tf/J (BTBR) mice to conduct behavioral tests assessing autistic‐like phenotypes. We evaluated hippocampal neurogenesis through immunofluorescence and employed molecular biological techniques, along with RNA sequencing, to elucidate the underlying molecular mechanisms. Results: Our findings revealed that the administration of naringin alleviated autism‐associated behaviors in BTBR mice. RNA sequencing analysis indicated that naringin facilitated the recovery of impaired hippocampal neurogenesis in these mice, as evidenced by an increase in doublecortin (DCX)‐positive cells and neuronal progenitor cells (NPCs) in the dentate gyrus (DG). Furthermore, we confirmed that the cannabinoid receptor type‐1 (CB1) plays a role in the therapeutic effects of naringin. Conclusions: This research highlights the potential of naringin as a promising treatment option for autism spectrum disorder (ASD) and suggests that targeting hippocampal neurogenesis through the CB1 receptor may be an effective strategy.
- 28 November 2025
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 31 (12) , e70654
Open AccessNaringin Alleviates Autistic‐Like Behaviors in BTBR Mice Through Cannabinoid Receptor Type 1‐Mediated Restoration of Hippocampal Neurogenesis
Background: Naringin, a flavanone glycoside (naringenin 7‐O‐neohesperidose), exhibits a broad range of pharmacological activities, including neuroprotection. However, its effects on autistic‐like behavior have not been extensively studied. Methods: In this investigation, we utilized the autistic BTBR T + tf/J (BTBR) mice to conduct behavioral tests assessing autistic‐like phenotypes. We evaluated hippocampal neurogenesis through immunofluorescence and employed molecular biological techniques, along with RNA sequencing, to elucidate the underlying molecular mechanisms. Results: Our findings revealed that the administration of naringin alleviated autism‐associated behaviors in BTBR mice. RNA sequencing analysis indicated that naringin facilitated the recovery of impaired hippocampal neurogenesis in these mice, as evidenced by an increase in doublecortin (DCX)‐positive cells and neuronal progenitor cells (NPCs) in the dentate gyrus (DG). Furthermore, we confirmed that the cannabinoid receptor type‐1 (CB1) plays a role in the therapeutic effects of naringin. Conclusions: This research highlights the potential of naringin as a promising treatment option for autism spectrum disorder (ASD) and suggests that targeting hippocampal neurogenesis through the CB1 receptor may be an effective strategy.
- Open Access
- 1 June 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 6035-6055
Fullerenols Ameliorate Social Deficiency and Rescue Cognitive Dysfunction of BTBR T+Itpr3tf/J Autistic-Like Mice
Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition that affects social interaction and communication and can cause stereotypic behavior. Fullerenols, a type of carbon nanomaterial known for its neuroprotective properties, have not yet been studied for their potential in treating ASD. We aimed to investigate its role in improving autistic behaviors in BTBR T+Itpr3tf/J (BTBR) mice and its underlying mechanism, which could provide reliable clues for future ASD treatments. Methods: Our research involved treating C57BL/6J (C57) and BTBR mice with either 0.9% NaCl or fullerenols (10 mg/kg) daily for one week at seven weeks of age. We then conducted ASD-related behavioral tests in the eighth week and used RNA-seq to screen for vital pathways in the mouse hippocampus. Additionally, we used real-time quantitative PCR (RT-qPCR) to verify related pathway genes and evaluated the number of stem cells in the hippocampal dentate gyrus (DG) by Immunofluorescence staining. Results: Our findings revealed that fullerenols treatment significantly improved the related ASD-like behaviors of BTBR mice, manifested by enhanced social ability and improved cognitive deficits. Immunofluorescence results showed that fullerenols treatment increased the number of DCX+ and SOX2+/GFAP+ cells in the DG region of BTBR mice, indicating an expanded neural progenitor cell (NPC) pool of BTBR mice. RNA-seq analysis of the mouse hippocampus showed that VEGFA was involved in the rescued hippocampal neurogenesis by fullerenols treatment. Conclusion: In conclusion, our findings suggest that fullerenols treatment improves ASD-like behavior in BTBR mice by upregulating VEGFA, making nanoparticle- fullerenols a promising drug for ASD treatment.
- 1 June 2024
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 19, 6035-6055
Open AccessFullerenols Ameliorate Social Deficiency and Rescue Cognitive Dysfunction of BTBR T+Itpr3tf/J Autistic-Like Mice
Background: Autism Spectrum Disorder (ASD) is a neurodevelopmental condition that affects social interaction and communication and can cause stereotypic behavior. Fullerenols, a type of carbon nanomaterial known for its neuroprotective properties, have not yet been studied for their potential in treating ASD. We aimed to investigate its role in improving autistic behaviors in BTBR T+Itpr3tf/J (BTBR) mice and its underlying mechanism, which could provide reliable clues for future ASD treatments. Methods: Our research involved treating C57BL/6J (C57) and BTBR mice with either 0.9% NaCl or fullerenols (10 mg/kg) daily for one week at seven weeks of age. We then conducted ASD-related behavioral tests in the eighth week and used RNA-seq to screen for vital pathways in the mouse hippocampus. Additionally, we used real-time quantitative PCR (RT-qPCR) to verify related pathway genes and evaluated the number of stem cells in the hippocampal dentate gyrus (DG) by Immunofluorescence staining. Results: Our findings revealed that fullerenols treatment significantly improved the related ASD-like behaviors of BTBR mice, manifested by enhanced social ability and improved cognitive deficits. Immunofluorescence results showed that fullerenols treatment increased the number of DCX+ and SOX2+/GFAP+ cells in the DG region of BTBR mice, indicating an expanded neural progenitor cell (NPC) pool of BTBR mice. RNA-seq analysis of the mouse hippocampus showed that VEGFA was involved in the rescued hippocampal neurogenesis by fullerenols treatment. Conclusion: In conclusion, our findings suggest that fullerenols treatment improves ASD-like behavior in BTBR mice by upregulating VEGFA, making nanoparticle- fullerenols a promising drug for ASD treatment.